Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL

WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,

GlobeNewswireJul 22 08:00 ET

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Both studies achieved the primary and key secondary endpoints, with significant improvements observed as early as week 1.

Zacks Jul 17 10:05 ET

Optimistic Investors Push Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Up 30% But Growth Is Lacking

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shareholders are no doubt pleased to see that the share price has bounced 30% in the last month, although it is still struggling to make up recently lost

Simply Wall StJul 11 08:58 ET

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

Yahoo FinanceJul 10 11:23 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Mizuho Securities analyst Uy Ear maintains $Arcutis Biotherapeutics(ARQT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.3% and a total average return of 6.3%

Moomoo NewsJul 10 09:31 ET · Ratings

TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20

TD Cowen analyst Tyler Van Buren maintains $Arcutis Biotherapeutics(ARQT.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 44.

Moomoo NewsJul 10 07:34 ET · Ratings